Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + docetaxel + cisplatin (Shanghai Junshi Biosciences Co., Ltd., 670bf8)
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of toripalimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, administered alongside the chemotherapy agents docetaxel and cisplatin. Toripalimab functions as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to restore T-cell mediated anti-tumor activity. Docetaxel is a taxane that promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest, while cisplatin is a platinum-based agent that forms DNA cross-links, interfering with DNA replication and transcription. This triplet regimen is being investigated as induction chemotherapy for localized hypopharyngeal squamous cell carcinoma (HSCC) to improve organ preservation rates and reduce tumor burden prior to definitive surgery or chemoradiotherapy.
- Brand names
- Tuoyi
- Other names
- JS001 + docetaxel + cisplatintoripalimab plus docetaxel and cisplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on toripalimab + docetaxel + cisplatin (Shanghai Junshi Biosciences Co., Ltd., 670bf8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + docetaxel + cisplatin (Shanghai Junshi Biosciences Co., Ltd., 670bf8).